Alvotech secured an additional term loan facility of $75 million with a maturity date of December 31, 2027, led by GoldenTree Asset Management. Alvotech is a biotechnology company focused on developing and manufacturing biosimilars.

Alvotech closed its previously announced underwritten public offering and the underwriters exercised their option to purchase additional ordinary shares. Alvotech is a biotechnology company focused on development and commercialization of biosimilars.

Alvotech entered into an Underwriting Agreement on June 15, 2026, for a public offering of 22,666,667 ordinary shares at $3.75 per share, with an additional 3,400,000 shares option exercised in full. The company also entered into subscription agreements for a private placement of 17,826,666 shares at the same price, which is expected to close within seven business days of the public offering. Net proceeds from the public offering are expected to be approximately $91.20 million. Alvotech is a biotechnology company focused on developing and manufacturing biosimilars.

On June 15, 2026, Alvotech notified Jefferies LLC of the suspension and termination of its ATM Prospectus Supplement related to the issuance of ordinary shares under the Open Market Sale Agreement dated June 14, 2024. The company will not sell securities under this agreement until a new prospectus supplement or registration statement is filed, though the Sales Agreement itself remains in effect. Alvotech is a biopharmaceutical company that develops and manufactures biosimilar medicines.

Alvotech announced that the FDA has accepted its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) lyophilized vial. The company also released its unaudited condensed consolidated interim financial statements for the first three months of 2026.